Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867619 | 0.85 | KIF11 (0.50) | ERN1TDP1PTP4A3KIF11HTT | |
| SCHEMBL8928304 | 0.85 | ERN1 (0.48) | ERN1TDP1PTP4A3KIF11CYP1A2 | |
| SCHEMBL502871 | 0.84 | TDP1 (0.55) | ERN1TDP1PTP4A3KIF11CYP1A2 | |
| SCHEMBL30266598 | 0.78 | KIF11 (0.44) | ERN1KIF11PTPN1KDM4E | |
| SCHEMBL1073123 | 0.78 | KIF11 (0.44) | ERN1KIF11PTPN1KDM4E | |
| SCHEMBL663646 | 0.78 | CES2 (0.50) | ERN1KIF11HSD17B10KDM4E | |
| SCHEMBL6853514 | 0.78 | KIF11 (0.53) | ERN1TDP1KIF11RAB9ATSHR | |
| SCHEMBL13551071 | 0.77 | PTP4A3 (0.43) | TDP1PTP4A3CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7272180 | 0.76 | ERN1 (0.47) | ERN1TDP1PTP4A3KIF11CYP1A2 | |
| SCHEMBL3603802 | 0.76 | ERN1 (0.52) | ERN1TDP1PTP4A3KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250262205-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4585596-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-07-16 | — | — | EP | disclosed |
| US-12318383-B2 | Dual MAGL and FAAH inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-117736178-B | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4424683-A2 | DUAL MAGL AND FAAH INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3595665-B1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118271288-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240158408-A1 | Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof | 280 BIO, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20060252757-A1 | Cinnoline compounds | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2006094034-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS | WYETH (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006044454-A1 | 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| CN-1016868-B | Process for preparing 5-aralkyl-4-alkoxy-2 (5H) -furanone | SCHWABE WILLMAR GMBH & CO (DE) | 1992-06-03 | — | — | CN | disclosed |
| EP-0247320-B1 | 5-ARYLALKYL-4-ALKOXY-2(5H)-FURANONES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION AS WELL AS THEIR APPLICATION AS THERAPEUTICALLY ACTIVE INGREDIENTS | SCHWABE WILLMAR GMBH & CO (DE) | 1990-12-27 | — | — | EP | disclosed |
| US-4855320-A | ANTICONVULSANTS, ANTIEPILEPTICS | DR. WILLMAR SCHWABE GMBH & COMPANY (DE) | 1989-08-08 | — | — | US | disclosed |
| EP-0247320-A2 | 5-Arylalkyl-4-alkoxy-2(5H)-furanones, intermediates and process for their preparation as well as their application as therapeutically active ingredients | Dr. Willmar Schwabe GmbH & Co. (DE) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158408-A1 | Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof | MTOR, AKT1, AKT2 | ERN1 2181/4885TDP1 1880/4885PTP4A3 1636/4885 |
| US-20250262205-A1 | DUAL MAGL AND FAAH INHIBITORS | FAAH, FAAH2, MAG | ERN1 3423/4885TDP1 3538/4885PTP4A3 2174/4885 |
| US-12318383-B2 | Dual MAGL and FAAH inhibitors | FAAH, FAAH2, MAG | ERN1 3423/4885TDP1 3538/4885PTP4A3 2174/4885 |
| US-20060252757-A1 | Cinnoline compounds | NR1H3, NR1H2, CNR1 | ERN1 2015/4885TDP1 4009/4885PTP4A3 4475/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | ERN1 774/4885TDP1 2538/4885PTP4A3 3215/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | ERN1 2548/4885TDP1 2710/4885PTP4A3 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.